M.D. Anderson Cancer Center
An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.
Primary Objectives: To determine the safety and tolerability of CBP-1019 combinations (Regimen A: CBP-1019 plus FOLFOX; Regimen B: CBP-1019 plus FOLFOX with bevacizumab; Regimen C: CBP-1019 plus pembrolizumab; and Regimen D: CBP-1019 plus enzalutamide) in metastatic solid tumors of epithelial origin. To determine the ORR of CBP-1019 combinations in selected metastatic solid tumors of epithelial origin. Secondary Objective: To evaluate other indicators of the antitumor activity of CBP-1019 combinations. Exploratory Objectives: To explore potential biomarkers associated with response/resis…
Inclusion Criteria 1. Patients must have histologically or cytologically confirmed malignancy of epithelial origin other than ovarian cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Patients must have received at least one prior line of systemic standard therapy, and have either disease progression or intolerable toxicity after standard treatment. 2. In the dose expansion, Regimen A will enroll patients with metastatic pancreatic cancer with concurrent oxaliplatin and irinotecan-free interval ≥4 months (…
Given by vein (IV)
Given by vein (IV)
Given by vein (IV)
Given by vein (IV)
Given by vein (IV)
Given by vein (IV)
Given by mouth
Arctuva estimate
Verify or correct the compensation shown for this listing.